Profile

Dmitriy Berenzon, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

125 Ratings
10 Comments
 

Dmitriy Berenzon, M.D.

Assistant Professor,

Clinical Interests

Acute and Chronic Leukemia, Essential Thrombocythemia, Hematologic Malignancies, Multiple Myeloma, Polycythemia Vera, Primary Myelofibrosis

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Additional Languages

Russian

Education & Training

  • M.D., I.P. Pavlov Leningrad-Russia, 1995
  • Residency, Internal Medicine, I.P. Pavlov Medical University, 1997
  • Residency, Internal Medicine, Methodist Hsp Of Brooklyn, 2007
  • Fellowship, Hematology And Oncology, Mount Sinai School of Medicine, 2010

Board Certifications

  • American Board of Internal Medicine, Internal Medicine

NPI Number

  • 1669631479
Dmitriy Berenzon, M.D.

Doctor Rating

4.6 out of 5

125 Ratings
10 Comments
 

Dmitriy Berenzon, M.D.

Assistant Professor, Hematology & Oncology
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-716-1808 | Department: 336-716-4464

Recent Publications

Wu D, Guo X, Su J, Chen R, Berenzon D, Guthold M, Bonin K, Zhao W, Zhou X. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Biochim Biophys Acta. 2015;1853(2):338-347.

Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015;39(9):945-949.

Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;33(33):3953-3960.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. J Clin Oncol. 2015;33(15 Suppl):7015.

Wu D, Guo XY, Su J, Chen RY, Berenzon D, Bonin K, Guthold M, Zhao WL, Zhou XB. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway [abstract]. Clin Cancer Res. 2015;21(Suppl 17):A09.

Verstovsek S, Saltzman M, Dakhil S, Bessudo A, Lyons R, Jawien W, Berenzon D, Mena R, Glidden P, Choy G, Laliberte R, Hamilton B,. Phase 2 study of a novel controlled-release formulation of anagrelide (Gale-401) in subjects with myeloproliferative neoplasm (Mpn)-related thrombocytosis [abstract]. Haematologica. 2015;100(Suppl 1):263.

Troung PV, Saltzman M, Bessudo A, Jawien W, Lyons RM, Berenzon D, Mena R, Wingate-Pearse N, Barriere O, Beeson HE, Glidden PF, Choy GS, Verstovsek S. Final results of anagrelide controlled-release (GALE-401) safety, efficacy and pharmacokinetics in subjects with myeloproliferative neoplasms (MPN)-related thrombocytosis [abstract]. Blood. 2015;126(23):4074.

Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL. The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2556.

Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S. Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2102.

Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47-55.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL. The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Blood. 2014;124(21):3744.

Chaurasia P, Berenzon D, Hoffman R. Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood. 2011;117(17):4632-4641.

Chaurasin P, Berenzon D, Hoffman R. Chromatin modifying agents promote the ex vivo production of functional human erythroid progenitor cells [abstract]. Blood. 2010;116(21):154.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Assistant Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Essential Thrombocythemia, Hematologic Malignancies, Multiple Myeloma, Polycythemia Vera, Primary Myelofibrosis
Dmitriy Berenzon, M.D.

Dmitriy Berenzon, M.D.

Assistant Professor, Hematology & Oncology
Comprehensive Cancer Center

Doctor Rating

4.6 out of 5

Dmitriy Berenzon, M.D.125 Ratings
10 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.6
CP explanations of prob/condition
4.7
CP spoke using clear language
4.7
Friendliness/courtesy of CP
4.7
Likelihood of recommending CP
4.6
Patients' confidence in CP
4.7
Time CP spent with patient
4.6
Wait time at clinic
3.7



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

3/28/2016

Always tries to help me like my family.

2/23/2016

I consider *Dr. Berenzon a top flight Oncologist.

12/31/2015

Bad

9/9/2015

Very impressed.

8/17/2015

Dr. had reviewed my chart and history very thoroughly. He spent a great deal of time explaining the disorder they were checking for and reassuring me. He emailed after the test to say it was as he had suspected and I had no worries at this time. His email made me smile!

8/11/2015

Real courtesy and concern in a difficult time.

8/6/2015

He's a brilliant doctor.

7/29/2015

Very good.

7/20/2015

Good.

6/10/2015

I would recommend Dr. Berenzon and Dr. Holland to any of my family or friends

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.